IntelGenx Corp. set to file NDA for antidepressant

October 10, 2008

SAINT LAURENT, QUEBEC and GREAT FALLS, VIRGINIA, (MARKET WIRE ) - Oct. 9, 2008 - IntelGenx  Corp. (TSX:IGX)(OTCBB:IGXT) ("IntelGenx") and Cary Pharmaceuticals Inc. ("Cary Pharma") today announced positive results from a clinical trial on  its  antidepressant CPI 300. The results from the bioequivalence study undertaken in September 2008 confirm that CPI 300 is bioequivalent to the reference product.  IntelGenx and Cary Pharma will be filing a New Drug Application (“NDA”) (505(b)(2) based on the successful results of this study.  Approval of the product is expected during the second half of 2009. 

“This is fantastic news as it clearly demonstrates that our development team has mastered all of the hurdles required to file an NDA for a patented product to compete in a $1.6 billion market,” said Dr. Horst Zerbe, President and CEO of IntelGenx.  He added “We are now able to concentrate our efforts on completing the compilation of documentation for the 505(b)(2) NDA filing with the FDA. I am very proud of our team of experts who not only successfully developed this product within the allotted timeframe, but also within budget.”

“Our research shows that more than 1.0 million  prescriptions were dispensed for the higher dosage of this antidepressant during 2007  and we will be the sole provider of this medication in a single tablet. I am very excited by these results” said Douglas D. Cary, President and CEO of Cary Pharmaceuticals.

CPI 300:
CPI-300 was formulated using IntelGenx’s proprietary controlled release technology. It contains a new strength of antidepressant developed to complete the dosing options for physicians who currently prescribe the drug.   CPI-300 provides a more convenient dosing option for those patients currently taking the higher strength.  It will be indicated for the treatment of major depressive disorder (MDD). 

Major Depressive Disorder:
Major depressive disorder is also known as major depression, clinical depression, or unipolar depression. Major Depressive Disorder is the leading cause of disability in the U.S. for ages 15-44. It affects approximately 14.8 million American adults, or about 6.7 percent of the U.S. population age 18 and older in a given year.

About IntelGenx Corp.:
IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company's research and development pipeline includes products for the treatment of pain, hypertension, osteoarthritis, and depressive disorders. More information is available about the company at

About Cary Pharmaceuticals Inc.:
Cary Pharmaceuticals Inc. is a specialty pharmaceutical company located in Northern Virginia. The company's product pipeline includes CPI-300 for the treatment of depression, and QuitPak(R) for smoking cessation.   

Forward Looking Statements:
This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

The TSX and OTCBB have neither approved nor disapproved of the information contained herein.

 Dr. Horst G. Zerbe President and CEO
 IntelGenx Corp.
(514) 331-7440x201

Douglas D. Cary, President and CEO
Cary Pharmaceuticals Inc.
Website :